Understanding the link between progranulin deficiency and reduced enzyme activity in dementia
The cause and effect of reduced ò-glucocerebrosidase activity in the setting of progranulin deficiency
This study is looking at how a protein called progranulin works with an enzyme in the brain to understand frontotemporal dementia better, and it aims to find new ways to help people with this condition by improving brain health.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10857262 on NIH RePORTER |
What this research studies
This research investigates how a protein called progranulin interacts with an enzyme known as beta-glucocerebrosidase in the context of frontotemporal dementia, a type of early-onset dementia. The study aims to explore the effects of progranulin deficiency on lysosomal function, which is crucial for cellular health. By examining brain samples from patients and animal models, the researchers hope to identify potential therapeutic targets that could help mitigate the effects of this deficiency. The ultimate goal is to develop treatments that can prevent or delay the onset of dementia in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with frontotemporal dementia, particularly those with known progranulin mutations.
Not a fit: Patients with other forms of dementia not related to progranulin deficiency may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the quality of life for patients with frontotemporal dementia caused by progranulin mutations.
How similar studies have performed: Previous research has shown promise in targeting lysosomal dysfunction in neurodegenerative diseases, suggesting that this approach may yield beneficial results.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Boyle, Nicholas Ryan — University of Alabama at Birmingham
- Study coordinator: Boyle, Nicholas Ryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.